Document is current
Any future updates will be listed below
-
Authors
Slingluff, Craig L.
Ernstoff, Marc S.
Lawson, David
Delman, Keith A.
Hanks, Brent A.
Gastman, Brian
Mauldin, Ileana S.
Olson, Walter C.
Ninmer, Emily K.
Gradecki, Sarah E.
Smith, Kelly T.
Gru, Alejandro
Ramchurren, Nirasha
Morishima, Chihiro
Fling, Steven P.
Kaiser, Judith C.
Cheever, Martin A.
-
Funding
Funding for this research was provided by:
NIH/NCI (P30 CA44579)
NIH/NCI (U01 CA154967)
Incyte
Commonwealth Foundation for Cancer Research
Rebecca Clary Harris Fellowship, University of Virginia
- License Information
-
More Information
Article History
Received: 30 June 2026
Accepted: 7 September 2026
First Online: 2 October 2026
Declarations
Conflict of interest: Brian Gastman: Now works for Iovance. Brent Hanks: Regeneron—scientific advisory board/research funding; Merck—research funding; Amgen – consulting. Craig Slingluff has the following disclosures: Research support to the University of Virginia from Celldex (funding, drug), Glaxo-Smith Kline (funding), Merck (funding, drug), Theraclion (device staff support); Funding to the University of Virginia from Polynoma for PI role on the MAVIS Clinical Trial; Funding to the University of Virginia for roles on Scientific Advisory Boards for CureVac and Epitopea. Also, C.L.S. has received licensing fee payments through the UVA Licensing and Ventures Group (UVA LVG) for patents for peptides used in these cancer vaccines. Patents relevant to peptides in this vaccine include United States Patent # 6,660,276; 6,558,671; and 7,019,112; however, the terms of those patents have expired. He holds other patents for peptides in melanoma vaccines (US Patent number US 9,345,755 B2), plus one submitted, all managed by UVA LVG. All other authors declare that they have no competing interests or disclosures.
